| Literature DB >> 23852648 |
Daisuke Sakai1, Taroh Satoh, Yukinori Kurokawa, Toshihiro Kudo, Kazuhiro Nishikawa, Yoshio Oka, Toshimasa Tsujinaka, Toshio Shimokawa, Yuichiro Doki, Hiroshi Furukawa.
Abstract
Irinotecan is a key drug in second- or further-line chemotherapy for patients with advanced gastric cancer. Continuous administration of trastuzumab beyond first progression is expected to contribute to the benefit of chemotherapy for human epidermal growth factor receptor 2-positive gastric cancer. The aim of this trial is to evaluate the efficacy and safety of combination chemotherapy with trastuzumab and irinotecan in Japanese patients with advanced human epidermal growth factor receptor 2-positive chemo-refractory gastric cancer. The primary endpoint is the disease control rate. The secondary endpoints are adverse events, overall response rate, time to treatment failure, progression-free survival, overall survival and response rate stratified by prior trastuzumab use. A total of 30 patients will be enrolled in this Osaka Gastrointestinal Cancer Chemotherapy Study Group trial.Entities:
Keywords: chemo-GI tract HER2-positive; irinotecan; trastuzumab
Mesh：
Substances：
Year: 2013 PMID： 23852648 DOI： 10.1093/jjco/hyt083
Source DB: PubMed Journal: Jpn J Clin Oncol ISSN： 0368-2811 Impact factor: 3.019